Landos Biopharma’ Presents on Phase 2 Data of Omilancor in Ulcerative Colitis

 Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated clinical trial site feasibility studies for the planned global pivotal Phase 3 trial of omilancor in UC

https://finance.yahoo.com/news/landos-biopharma-phase-2-data-110000903.html